Health as a fundamental value. Towards an inclusive and equitable pharmaceutical strategy for the European Union

On behalf of the Interest Group on Supranational Biolaw of the European Association of Health Law (EAHL IG Biolaw) and the I-BioLex research project (ANR-20-CE26-0007-01), Éloïse Gennet and Aurélie Mahalatchimy have been coordinating, since September 2021, the thematic network on the pharmaceutical strategy on the European Health Policy Platform (EUHPP) of the European Commission. The thematic network of the EAHL IG Biolaw, selected by the European Commission and by the users of the EUHPP platform, is entitled “Health as a fundamental value. Towards an inclusive and equitable pharmaceutical strategy for the European Union”. This network enables to link the EAHL IG Biolaw, exclusively constituted by researchers and academics in the field of health law in Europe, on the one hand with the European Commission and in particular DG Health, and on the other hand with socio-economic actors interested in EU law applicable to medicinal products and medical devices (patient representatives, representatives of health professionals or non-governmental organizations in the field of health). After several months of fruitful exchanges, the final joint statement which was very favorably received by DG Health and endorsed by several organizations (including the President of Aix-Marseille University and the CNRS) has been presented at the EU Health Policy Platform Annual Meeting 2022 at the European Commission and published on the EUHPP in May 2022.